BioSpace News Archive

New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degeneration I n the experimental allergic uveitis (EAU) disease model nomacopan reduce d Th17 effector T cell and macrophage activity in addition to known downregulation of neutrophils Long-acting forms of nomacopan were at least as effective in downregulating disease in EAU model as standard of care dexamethasone, which is associated with steroid related side effects

2021 Awards Recognize Top Urologists, Honor Service to Specialty and Society

In support of public health efforts to encourage flu vaccinations and to provide an easy mode of transportation to flu shot locations across Metro-Boston, Blue Cross Blue Shield of Massachusetts (“Blue Cross”) will offer free Bluebikes rides during National Influenza Vaccination Week , December 6-12 . Complimentary trips will be av

Attune Medical, a breakthrough medical device company with a technology platform based on targeted temperature management using the esophageal space, has achieved significant corporate milestones as part of the company’s aggressive growth plan. The company’s ongoing support of clinical research for emerging temperature management applications and the ensoETM has resulted in the first major peer-reviewed clinical public

Business Activity Index at 58%; New Orders Index at 57.2%; Employment Index at 51.5%; Supplier Deliveries Index at 57%

Immunovia AB (publ) (“Immunovia”) announced today that the following members of the Board of Directors have purchased shares in the company: Member Number of Shares Total Investment Ann-Christine Sundell 2,500 292,500 SEK Mimmi Ekberg 451

Genotox Laboratories, an Austin, Texas based company, has announced the launch of MyTruthTest At Home COVID-19 Test Kits with 24-hour turnaround on RT-PCR test results, in most cases. “We are

Generous grant enables USO’s expansion of programs providing pandemic relief and recovery and ensures resilience of military communities in Indiana, the U.S. and the world

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or “the Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced it will participate in the LD Micro Virtual Main Event 2020 Conference. 180 Life Sciences CEO Dr. James Woody will present on Tuesday, December 15th at 1:40

Minister of Transport praises the commitment of the pharmaceutical service provider during global turbulent times Support of environmentally friendly mobility concepts Use of green technologies at all German Vetter sites Carbon dioxide neutrality and environmental re-certification